Drug profile · INN
valganciclovir hydrochloride
VALIXA PARTIAL CHANGE APPROVAL
valganciclovir hydrochloride (VALIXA PARTIAL CHANGE APPROVAL) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — valganciclovir hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
valganciclovir hydrochloride (VALIXA PARTIAL CHANGE APPROVAL) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human herpesvirus 1 DNA polymerase inhibitor
Primary target: DNA polymerase catalytic subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is valganciclovir hydrochloride?
valganciclovir hydrochloride (VALIXA PARTIAL CHANGE APPROVAL) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for valganciclovir hydrochloride?
VALIXA PARTIAL CHANGE APPROVAL is a marketed brand name for valganciclovir hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of valganciclovir hydrochloride?
valganciclovir hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.